Navigation Links
As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
Date:3/26/2009

Twenty Percent of Surveyed MCO Pharmacy Directors Say They Will Alter Reimbursement of TNF-alpha Inhibitors for Juvenile Idiopathic Arthritis and Pediatric Crohn's Disease, According to a New Report from Decision Resources

WALTHAM, Mass., March 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 30 percent of surveyed rheumatologists have altered their prescription patterns for juvenile idiopathic arthritis and more than 10 percent have altered their prescription patterns for adult rheumatoid arthritis in response to the Food and Drug Administration's (FDA) investigation into the malignancy risk associated with TNF-alpha inhibitors.

In June 2008, the FDA launched an investigation into the malignancy risk associated with TNF-alpha inhibitors in pediatric and juvenile populations being treated for autoimmune diseases. Concerns were raised when 30 cases of cancer in pediatric and juvenile patients being treated for rheumatoid arthritis and Crohn's disease were reported between 1998 and 2008.

The new Physician & Payer Forum report entitled TNF-alpha Inhibitors in Pediatric Crohn's Disease and Juvenile Idiopathic Arthritis: How Will Physicians and Payers Balance Effective Treatments and Serious Safety Concerns? finds that, of the rheumatologists that have altered their prescription patterns for juvenile idiopathic arthritis, 71 percent say that they prescribe conventional disease-modifying antirheumatic drugs more frequently than they had in the past. Nearly 60 percent of surveyed gastroenterologists say they have altered their prescription patterns for pediatric Crohn's disease -- of these gastroenterologists, 42 percent indicate that they restrict TNF-alpha inhibitors to patients with more severe disease. Furthermore, 45 percent of gastroenterologists say that they have altered their prescribing habits in adult Crohn's disease patients.

The report also finds that one out of five surveyed managed care organization (MCO) pharmacy directors indicate that they will alter their reimbursement of TNF-alpha inhibitors for the treatment of juvenile idiopathic arthritis and pediatric Crohn's disease.

"Twenty percent of surveyed MCO pharmacy directors will alter their reimbursement of TNF-alpha inhibitors for juvenile idiopathic arthritis or pediatric Crohn's disease in the light of the FDA investigation," said Decision Resources Analyst Dancella Fernandes, Ph.D. "MCOs that plan to alter the reimbursement of TNF-alpha inhibitors expect to be more cautious in granting approval, but none cite the intention of routinely refusing reimbursement for autoimmune indications."

TNF-alpha Inhibitors in Pediatric Crohn's Disease and Juvenile Idiopathic Arthritis: How Will Physicians and Payers Balance Effective Treatments and Serious Safety Concerns? is based on a U.S. survey of 71 rheumatologists, 71 gastroenterologists, and 20 managed care organization (MCO) pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                            Decision Resources, Inc.
    Christopher Comfort                           Elizabeth Marshall
    781-296-2597                                  781-296-2563
    ccomfort@dresources.com                       emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cowden Associates Releases Eighth-Annual Employee Benefit Survey Results
2. China Medicine Announces Record Fourth Quarter and 2008 Results
3. Londons First Science-Based Cellulite Massage Guarantees Results for Londons Cellulite Sufferers
4. Boys Skin Care Range Finds Interesting Results
5. Surgical Care Affiliates Announces Investor Conference Call to Discuss 2008 Fourth Quarter and Year-End Results
6. Subtle Fillers Bring Breathtaking Results; The Neigel Center for Cosmetic and Laser Surgery Hosts Its March 27th Filler Day Specials!
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
8. Global Med Technologies(R), Inc. to Report Fourth Quarter and Year End Financial Results Today
9. Discovery may result in new test to determine predisposition to cancer
10. Cord Blood America Announces Results of Shareholder Special Meeting
11. Why Are Healthcare Information Manufacturers Free of All Liability When Their Products Can Result in Medical Errors?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: